People: The key of collective success
Commitment, creativity and performance: these values are the foundation that underpins DIAGAST’s strategy, enabling it to satisfy our staff, shareholders, suppliers and customers on all levels. As a player in the world health sector, we are committed to focusing our energy on the development and high quality of our products, just as we are committed to allowing each employee to flourish in the DIAGAST world.
DIAGAST in numbers
- 223 employees
- 39,9 million euros in turnover (2021)
- 2 subsidiaries in India and Spain
- Operations in more than 100 countries
- More than 60% of business via exports
- 10% of turnover invested in R&D
- 30 blood tests performed every second worldwide with DIAGAST
- 86/100: Gender Equality Index Score (2022)
1968 - THE VERY BEGINNING
Sale of polyclonal sera for blood grouping.
1984 - INNOVATION BECAME A TRUE "TRADEMARK
Start of production of monoclonal antibodies in fermentors at the Lille's Regional Transfusion Center.
1988 - DIAGAST IS HENCEFORTH A STANDALONE COMPANY
Creation of DIAGAST with the industrial production of monoclonal antibodies.
1997 - FIRST STEP IN CERTIFICATION
ISO 9001-1994 Certification.
2003 - STRONG COMMITMENT TO QUALITY ASSURANCE SINCE 1997
ISO 9001:2000, ISO 13485:2001 and EC Marking.
2004 - MAGNETIC ATTRACTION OF A BRAND NEW TECHNOLOGY
Launch of EM®Technology, a new technology based on the RBC's magnetization.
2005 - CREATION OF A SUBSIDIARY IN SPAIN
DIAGAST Iberica is born.
2008 - ON THE ROAD TO NEW MARKETS IN NORTH AMERICA
FDA approval received in the USA and supply of reagents used in American blood banks.
2009 - QWALYS® 3: A NEW ERA OF ABSOLUTE PERFORMANCE
Third generation of QWALYS®.
2010 - DIAGAST IS BRANCHING OUT INTO THE ASIAN MARKETS
Subsidiary opened in India: DIAGAST India.
2012 - M-TRAP®: A COMPLETE BREAKTHROUGH VS THE EXISTING TECHNOLOGIES
Launch of M-TRAP®, a new technology for determining blood groups, and a new bedside card ABTest Card®.
2014 - FIRST STRATEGIC ACQUISITION FOR DIAGAST
Takeover of the start-up ABODiag and acquisition of new patents.
2016 - LAUNCH OF ABD PAD®
An innovative IVDMD for the confirmation of manual blood group, in 3 steps and 30 seconds.
2017 - QWALYS 3® EVO WHEN QWALYS® IS REINVENTING ITSELF
A STAT function, a dynamic scheduler and a new user interface: 3 news features that make the difference.
2019 - NEW INDUSTRIAL PREMISES
It doubles our production capacities and provides an industrial resource offering the highest levels of performance
Be part of the adventure and join our teams!